{"nctId":"NCT03596164","briefTitle":"An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004","startDateStruct":{"date":"2018-07-09","type":"ACTUAL"},"conditions":["Short Bowel Syndrome"],"count":11,"armGroups":[{"label":"Teduglutide 0.05 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Teduglutide","Device: Syringe","Device: Needle","Device: Vial Adapter for Device"]}],"interventions":[{"name":"Teduglutide","otherNames":[]},{"name":"Syringe","otherNames":[]},{"name":"Needle","otherNames":[]},{"name":"Vial Adapter for Device","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nParticipants who meet all of the following criteria will be enrolled in this study:\n\n1. Ability to voluntarily provide written, signed, and informed consent to participate in the study.\n2. Completion of the SHP633-306 study or participation in TED-C14-004 (NCT02340819) Stage 3 or Stage 4.\n3. Females of childbearing potential must agree to comply with the contraceptive requirements of the protocol.\n4. An understanding, ability, and willingness to fully comply with study procedures and restrictions.\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume","description":"The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\\*7. Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Weekly PS Volume","description":"The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\\*7. Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.45","spread":"7.908"},{"groupId":"OG001","value":"-8.67","spread":"7.450"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Weekly PS Volume","description":"The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\\*7. Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.55","spread":"41.411"},{"groupId":"OG001","value":"-52.52","spread":"39.828"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Days Per Week of PS","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"3.30"},{"groupId":"OG001","value":"-2.0","spread":"3.42"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Plasma Citrulline Levels","description":"Plasma citrulline was measured as an assessment of enterocyte mass. Plasma samples were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.96","spread":"5.568"},{"groupId":"OG001","value":"19.15","spread":"18.851"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Change From Baseline in Laboratory Values","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in 48-Hour Urine Output","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"428.8","spread":"286.57"},{"groupId":"OG001","value":"308.6","spread":"589.36"},{"groupId":"OG002","value":"352.3","spread":"486.54"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Change From Baseline in BMI","description":"Baseline data refer to the baseline of core studies (SHP633-306 \\[NCT03663582\\] or TED-C14-004 \\[NCT02340819\\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":4},"commonTop":["Nasopharyngitis","Influenza","Hypokalaemia","Anal abscess","Back pain"]}}}